About Us

Today, the majority of treatments for these degenerative diseases are palliative, focusing on alleviating symptoms alone. As pioneers in the science surrounding programmed cell death mechanisms and their connection to age-related degenerative diseases, Sironax was co-founded in 2017 by Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, who recognized the growing need for therapies that could directly address disease pathology. 

With operations in the United States, China, Switzerland, and Australia, Sironax has a growing global team of more than 170 employees. Our team, with decades of global pharmaceutical R&D experience, shares a vision of shifting the treatment paradigm to ultimately improve the lives of millions of patients worldwide.